

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

RESIGNATION OF NON-EXECUTIVE DIRECTOR CHANGE IN COMPOSITION OF AUDIT COMMITTEE

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of Innovent Biologics, Inc. (the “**Company**”) hereby announces that Mr. Shuyun Chen (“**Mr. Chen**”) has tendered his resignation as a non-executive Director to dedicate time to his other professional commitments, with effect from February 25, 2022. Upon Mr. Chen's resignation, Mr. Chen also resigned from his role as member of the audit committee of the Board (the “**Audit Committee**”) and the strategy committee of the Board (the “**Strategy Committee**”).

Mr. Chen has confirmed that (i) he has no claim against the Company in respect of his resignation and there is no disagreement between him and the Board; and (ii) there are no matters that need to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company in relation to his resignation.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Chen for his valuable contribution to the Company during his tenure of office as a non-executive Director and member of the Audit Committee and the Strategy Committee.

The Company is in the process of identifying a suitable candidate to fill the vacancy after the resignation of Mr. Chen and to carry out necessary work thereafter as soon as practicable. In the meantime, Dr. Charles Leland Cooney, an independent non-executive Director, will act as a member of the Audit Committee, with effect from February 25, 2022.

By order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, February 25, 2022

As at the date of this announcement and following the above resignation of Director, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu and Dr. Kaixian Chen as Independent Non-executive Directors.